The Latest Thinking Regarding Adjuvant Pembrolizumab in Renal Cell Carcinoma Post-ASCO GU ‘22

Peer-Spectives

English - March 11, 2022 16:39 - 21 minutes - 39.9 MB
Science Education obr oncology cancer healthcare medical obroncology peerspectives robertfiglin Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients

Next Episode: DREAMseq Trial: What It Means for Metastatic Melanoma Treatment

Rana McKay, MD, Allan Pantuck, MD, and Robert Figlin, MD, discuss the recent update to the Keynote-564 study investigating adjuvant pembrolizumab in RCC and the impact on high-, medium-, and low-risk patients. They also talk about the Disease-Free Survival (DFS) endpoint, discussing the study with patients, and the recent NCCN guidelines update.